U16

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Relapsed or Refractory Non-Hodgkin's Lymphoma

Drug Information

Target Indication

Relapsed or Refractory Non-Hodgkin's Lymphoma

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BIOE

Bio Essence Corp

Related Pipeline

Skin Structures and Soft Tissue Infections

Lower Urinary Tract Symptoms

Ankylosing Spondylitis

Immunogenicity

Non-Small Cell Lung Cancer